It is an object of the present invention to produce an anti-CDH3 humanized antibody having lower immunogenicity, and to provide an anti-CDH3 humanized antibody drug conjugate comprising the aforementioned anti-CDH3 humanized antibody that more efficiently kills cancer cells expressing CDH3. The present invention provides a conjugate of an anti-CDH3 humanized antibody and a drug by conjugating a drug having cytotoxicity to an anti-CDH3 humanized antibody which comprises complementarity determining region sequences derived from the heavy chain variable region of an antibody produced by cells having Accession No. NITE BP-1536, and complementarity determining region sequences derived from the light chain variable region thereof, and which also comprises a heavy chain human subgroup III consensus framework sequence or a human germline sequence that is selected under optimal alignment as a framework region sequence of the heavy chain variable region, and a light chain human º subgroup I consensus framework sequence or a human germline sequence that is selected under optimal alignment as a framework region sequence of the light chain variable region.
